Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...

Graves Disease II: Pathophysiology

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Goiter

Goiter

Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026

Same author

THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Questionnaire Survey of Medical Thyroid Specialists in Korea on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients.

Endocrinology and metabolism (Seoul, Korea)·2026

Same author

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.

Thyroid : official journal of the American Thyroid Association·2026

Same author

Use of Thyroid Hormones in Patients with Hypothyroidism and Euthyroidism in the United States: American Association of Clinical Endocrinology International Collaboration with the THESIS Investigators.

AACE endocrinology and diabetes·2026

Same author

Who Benefits and When? Applying Circulating Tumor Human Papillomavirus DNA for Human Papillomavirus-Associated Oropharyngeal Carcinoma.

JCO oncology practice·2026

Same author

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

Management of Differentiated Thyroid Cancer.

Laszlo Hegedüs¹, Lori J Wirth², R Michael Tuttle³

¹Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense.

The New England Journal of Medicine

|June 17, 2026

Summary

This study introduces a dynamic risk stratification framework for thyroid cancer management. It aids personalized treatment decisions by integrating clinical, molecular, and patient factors for better outcomes.

More Related Videos

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Related Experiment Videos

Last Updated: Jun 19, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

"Sun's Seven-Step Technique" for Endoscopic En-Bloc Resection of Thyroid Cancer via the Chest-Breast Approach

Published on: November 28, 2025

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Area of Science:

Oncology
Endocrinology
Medical Decision Making

Background:

Thyroid cancer management requires dynamic risk stratification from nodule detection through follow-up.
Current approaches integrate clinicopathological staging with molecular risk characterization for tailored plans.
Management plans evolve based on disease natural history and treatment response.

Purpose of the Study:

To present a clinical framework for therapeutic decision-making in thyroid cancer.
To illustrate the application of this framework in diverse clinical scenarios.
To facilitate informed consensus and personalized management recommendations.

Main Methods:

Development of a clinical framework for risk-adapted thyroid cancer management.
Integration of clinicopathological staging and molecular risk data.
Case examples illustrating decision-making for active surveillance, minimalist therapy, and systemic treatments.

Main Results:

The framework provides a structured approach to compare risks, benefits, and patient preferences.
Demonstrates effective application in managing low-risk papillary thyroid cancer via active surveillance.
Highlights utility in guiding minimalist therapy for low- and intermediate-risk disease and systemic therapies for advanced cancer.

Conclusions:

The proposed framework supports personalized thyroid cancer management.
It aids in achieving informed consensus among clinicians and patients.
Dynamic risk stratification is key to optimizing therapeutic decision-making throughout the patient's journey.